期刊文献+

Investigation of the Drug Stability at the Amorphous State Using Thermal Analysis

Investigation of the Drug Stability at the Amorphous State Using Thermal Analysis
下载PDF
导出
摘要 Formulation of poorly water-soluble crystalline drugs in their amorphous counterpart is a common approach to enhance their biodisponibility. In this study, the amorphous forms of ketoprofen and flurbiprofen were obtained by supercooling of the melt in a DSC (differential scanning calorimetry) apparatus and then investigated, especially under the stability point of view. The average rate of molecular motions at any given temperature is probably the most important parameter to know for amorphous pharmaceutical materials, and it was used to explain and predict the stability of ketoprofen and flurbiprofen. A quantitative estimate of the product's behaviour upon storage is obtained with additional data, such as the heat capacity of crystalline and amorphous samples and the distribution of molecular relaxation times. Amorphous flurbiprofen demonstrated greater physical stability at any aging temperature tested, when compared to ketoprofen and a different dependence from aging temperature. Both amorphous drugs could he classified as "fragile" ones.
出处 《Journal of Chemistry and Chemical Engineering》 2012年第7期646-650,共5页 化学与化工(英文版)
关键词 KETOPROFEN FLURBIPROFEN amorphous form molecular mobility annealing experiments. 药物稳定性 非晶质 热分析 差示扫描量热法 状态 老化温度 分子运动 无定形
  • 相关文献

参考文献12

  • 1Huang, L. F.; Tong, W. Q. Impact of Solid StateProperties on Develop Ability Assessment of Drug Candidates. Adv. Drug Deliv. Rev. 2004, 56(3), 321-334.
  • 2Brittain, H. G. The Impact of Polymorphism on Drug Development: A Regulatory Viewpoint. Am. Pharm. Rev. 2000, 3, 67-68.
  • 3Vippagunta, S. R.; Brittain, H. G.; Grant, D. J. Crystalline Solids. Adv. Drug Deliv. Rev. 2001, 48(1), 3-26.
  • 4Bym, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikian, G. Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations. Pharm. Res. 1995, 12, 945-954.
  • 5Bruno, C. H.; Parks, M. What is the True Solubility Advantage for Amorphous Pharmaceuticals? Pharm. Res. 2000, 17(4), 397-404.
  • 6Hancock, B. C.; Zografi, G. Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. J. Pharm. Sci. 1997, 86, 1-12.
  • 7Martino, P. D. Molecular Mobility of the Paracetamol Amorphous Form. Chem. Pharm. Bull. 2000, 48, 1105-1108.
  • 8Angell, C. A. The Old Problems of Glass and the Glass Transition, and the Many New Twists. Proc. Natl. Acad. Sci. 1995, 92, 6675-6682.
  • 9Angell, C. A. Formation of Glasses from Liquids and Biopolymers.Science 1995, 267, 1924-1935.
  • 10Hancock, B. C.; Shamblin, S. L. Molecular Mobility of Amorphous Pharmaceuticals Determined using Differential Scanning Calorimetry. Thermochim. Acta. 2001, 380, 95-107.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部